Sponsored by an educational grant from Zoetis


  • The cytokine interleukin (IL)-31 is important in sending the signals to the brain that result in pruritus in dogs with canine atopic dermatitis (CAD).
  • A new generation of CAD therapeutics, including APOQUEL®, a Janus kinase inhibitor, and CYTOPOINT™, a monoclonal antibody that blocks canine IL-31, is now available.
  • APOQUEL (oclacitinib), an oral tablet, provides fast, effective, and safe relief—without the side effects of steroids—from itch associated with any allergic dermatitis and is particularly useful during the diagnostic workup of the allergic dog.
  • CYTOPOINT, a monthly injectable, provides sustained relief in dogs with CAD and can be used in dogs of any age, dogs with comorbidities, and in conjunction with other medications.

Sign in to continue reading this article

Not registered? Create an account for free to read full articles on www.cliniciansbrief.com.

To access full articles on www.cliniciansbrief.com, please sign in below.

Busy? Sign in Faster. Sign into www.cliniciansbrief.com with your social media account.
Up Next